- Home
- QDEL vs RLAY Comparison
QDEL vs RLAY Comparison
Compare QDEL & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QDEL | RLAY |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | QDEL | RLAY |
|---|---|---|
| Price | $33.07 | $7.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $39.33 | $16.00 |
| AVG Volume (30 Days) | 821.9K | ★ 2.1M |
| Earning Date | 02-11-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,714,400,000.00 | $8,355,000.00 |
| Revenue This Year | N/A | $19.96 |
| Revenue Next Year | $2.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.50 | $1.78 |
| 52 Week High | $46.24 | $9.04 |
Technical Indicators
Market Signals| Indicator | QDEL | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 42.01 |
| Support Level | $31.87 | $7.62 |
| Resistance Level | $35.58 | $8.38 |
| Average True Range (ATR) | 1.67 | 0.45 |
| MACD | 0.07 | -0.12 |
| Stochastic Oscillator | 61.04 | 28.48 |
Price Performance
Historical ComparisonAbout QDEL QuidelOrtho Corporation
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).